NU Skin Enterprises Inc

NU Skin Enterprises Inc(NUS)股票分析

$4.570

-0.117 (-2.56%)收盤時

Loading chart…
High
4.770
Open
4.700
VWAP
4.63
Vol
685.91K
Mkt Cap
536.41M
Low
4.550
Amount
3.18M
EV/EBITDA, TTM
2.16

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others.

AI analysis of NU Skin Enterprises Inc (NUS)

hold

NU Skin Enterprises Inc is currently not a strong buy. The stock is priced at 4.85, which is significantly lower than its 200-day simple moving average of 7.549, indicating a bearish trend. Additionally, the forward P/E ratio is 5.9032, suggesting it may be undervalued compared to its earnings potential, but the recent net income drop to -249798000 in Q2 2026 raises concerns about profitability. The RSI is at 52.765, indicating neutral momentum, and the stock has a year-to-date change of -49.95%, reflecting significant underperformance. The main risk is the negative net margin of -78.03% in Q2 2026, which indicates ongoing financial struggles.

Analyst Ratings (6)

Buy
3 Buy
1 Hold
2 Sell
Current: 4.57
最低
平均
最高

DA Davidson

2024-12-20

目標價

$7

Hold

Citigroup

2024-10-22

目標價

$6.75

Hold

DA Davidson

2024-08-12

目標價

$11

Hold

Citigroup

2024-08-09

目標價

$12

Hold

DA Davidson

2024-05-09

目標價

$13

Hold

估值指標

The current forward P/E ratio for NU Skin Enterprises Inc (NUS) is 5.84, compared to its 5-year average forward P/E of 11.27.

Forward P/E

Undervalued
5Y Average P/E
11.27
Current P/E
5.84
高估
16.18
低估
6.35

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
5.51
Current EV/EBITDA
2.16
高估
8.48
低估
2.54

Forward P/S

Undervalued
5Y Average P/S
0.54
Current P/S
0.15
高估
0.86
低估
0.21

Alphio AI Price Scenarios for NUS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NUS

$6.63

情境價格

B

Base

Base · 50%NUS

$6.29

情境價格

B

Bear

Bear · 25%NUS

$4.75

情境價格

Whales holding NUS

C

Castleknight Management LP

+ HoldingNUS

-15.87%

3M Return

事件時間軸

2026-08-10 (ET)

16:30:00

Sees Q3 Revenue of $310M to $340M

16:30:00

Cuts FY26 Revenue View to $1.28B-$1.35B

2026-05-07 (ET)

16:10:00

Nu Skin Q1 Revenue at $320.6M, Below Estimate

16:10:00

Sees Q2 Revenue of $330M-$360M

16:10:00

Company Confirms FY26 Revenue Outlook of $1.35B to $1.5B

資訊

NUS FAQ — answered by Alphio AI

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others. It operates in the Consumer Non-Cyclicals sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

NU Skin Enterprises Inc is currently not a strong buy. The stock is priced at 4.85, which is significantly lower than its 200-day simple moving average of 7.549, indicating a bearish trend. Additionally, the forward P/E ratio is 5.9032, suggesting it may be undervalued compared to its earnings potential, but the recent net income drop to -249798000 in Q2 2026 raises concerns about profitability. The RSI is at 52.765, indicating neutral momentum, and the stock has a year-to-date change of -49.95%, reflecting significant underperformance. The main risk is the negative net margin of -78.03% in Q2 2026, which indicates ongoing financial struggles.

6 analysts cover NUS: 3 rate it Buy, 1 Hold and 2 Sell.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始